Transgene

Transgene Long-term Debt

The Long-Term Debt of Transgene (TNG.PA) as of Nov 19, 2026 is 10.22 M EUR. In the previous year, Long-Term Debt was 15.96 M EUR — a change of -36.01% (lower).

Long-term Debt

10.22 MEUR

YoY

-36.01%

Last updated:

Long-Term Debt of Transgene is 2024 10.22 M EUR. Long-Term Debt of Transgene was 2023 15.96 M EUR. It decreases by -36.01% lower compared to the previous year.

The Transgene Long-term Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Long-term Debt
Date
Long-term Debt
Jan 1, 2017
31.89 M EUR
Jan 1, 2018
15.64 M EUR
Jan 1, 2019
14.39 M EUR
Jan 1, 2020
3.74 M EUR
Jan 1, 2021
2.45 M EUR
Jan 1, 2022
12.32 M EUR
Jan 1, 2023
15.96 M EUR
Jan 1, 2024
10.22 M EUR
The Transgene Long-term Debt history
YEARLong-term DebtYoY
10.22 MEUR-36.01%
15.96 MEUR+29.54%
12.32 MEUR+403.23%
2.45 MEUR-34.57%
3.74 MEUR-74.00%
14.39 MEUR-7.94%
15.64 MEUR-50.97%
31.89 MEUR-8.99%
35.04 MEUR+29.72%
27.01 MEUR-0.75%
27.22 MEUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Transgene Stock analysis

What does Transgene do? Transgene SA is a French biotechnology company specializing in the development and production of therapeutics, with a focus on cancer medications. It has a strong patent portfolio in the field of viral vectors, which are used for targeted gene therapy. The company's main areas of operation are clinical trials, research, and production. Transgene has research and production facilities in Strasbourg and Lyon, with over 100 employees. It has established partnerships with pharmaceutical companies, including Takeda Pharmaceuticals, for the development and marketing of therapeutics. Its flagship product, OncoVir-1®, is an immunomodulator that stimulates the immune system to fight tumor cells. Another promising product is TG4010, a therapeutic vaccine for non-small cell lung carcinoma. Transgene is an emerging company with a promising portfolio of cancer therapeutics, leveraging its expertise in viral vectors and collaborating closely with industry partners to expedite the development of marketable products. Transgene is expected to play a significant role in the development of new and innovative cancer treatments. Transgene is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Transgene stock

Long-Term Debt of Transgene is 10.22 M EUR in 2024.

Long-Term Debt of Transgene changed from 15.96 M EUR to 10.22 M EUR, representing a -36.01% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Long-Term Debt Transgene since 2006 – with annual values, charts, and detailed analysis.

Long-term debt represents obligations due after one year. It is a key component of a company's capital structure and leverage.

Long-Term Debt's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Long-Term Debt's Transgene historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Transgene

All Key Metrics — Transgene